본문으로 건너뛰기
← 뒤로

Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger.

1/5 보강
Anti-cancer agents in medicinal chemistry 📖 저널 OA 1.5% 2023: 0/1 OA 2025: 0/13 OA 2026: 1/52 OA 2023~2026 2025 Vol.25(4) p. 223-231
Retraction 확인
출처

Ye X, Wu Y, Zhang H

📝 환자 설명용 한 줄

Gastric cancer in advanced stages lacked effective treatment options.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Ye X, Wu Y, Zhang H (2025). Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger.. Anti-cancer agents in medicinal chemistry, 25(4), 223-231. https://doi.org/10.2174/0118715206329892240927081033
MLA Ye X, et al.. "Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger.." Anti-cancer agents in medicinal chemistry, vol. 25, no. 4, 2025, pp. 223-231.
PMID 39364863 ↗

Abstract

Gastric cancer in advanced stages lacked effective treatment options. claudin18.2 (CLDN18.2) is a membrane protein that is crucial for close junctions in the differentiated epithelial cells of the gastric mucosa, playing a vital role in barrier function, and can be hardly recognized by immune cells due to its polarity pattern. As the polarity of gastric tumor cells changes, claudin18.2 is exposed on the cell surface, resulting in immune system recognition, and making it an ideal target. In this review, we summarized the expression regulation mechanism of claudin18.2 both in normal cells and malignant tumor cells. Besides, we analyzed the available clinical results and potential areas for future research on claudin18.2-positive gastric cancer and claudin18.2-targeting therapy. In conclusion, claudin18.2 is an ideal target for gastric cancer treatment, and the claudin18.2-targeting therapy has changed the treatment pattern of gastric cancer.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반